Navigation Links
Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
Date:4/16/2013

SHENZHEN, China, April 16, 2013 /PRNewswire/ -- Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, today announced the achievement of the primary endpoint in the pivotal, registrational Phase 2 CHIPEL trial of Chidamide (Epidaza®), an orally active benzamide type of class I-selective histone deacetylase (HDAC) inhibitor. The NDA filing has been granted as an accelerated review by the China Food and Drug Administration (CFDA).

The CHIPEL trial was an open-labeled, single arm study in Chinese population to evaluate efficacy and safety of orally administrated Chidamide with relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, who had failed at least one prior systemic therapy. The CHIPEL trial surpassed an objective response rate (ORR) of at least 27%, the primary endpoint as a prior established agreement with CDE of CFDA, evaluated by both investigators and independent review committee. The trial results will be presented on June 3, 2013 at the Lymphoma and Plasma Cell Disorders Poster Discussion Session in the 2013 ASCO Annual Meeting, to be held in Chicago, USA.

"We are pleased to confirm that the trial has achieved its primary endpoint although the pathological subtypes of PTCL in Chinese population are significantly different from that in North America and Europe, where two FDA approved PTCL drugs, Pralatrexate and Romidepsin, were tested," stated Xian-Ping LU, Ph.D., Chief Executive Officer and Chief Scientific Officer of Chipscreen Biosciences Ltd. "We also expect efficacy and safety findings of Chidamide in combination with chemotherapeutic regimen for NSCLC in an ongoing Phase II trial."

About Chidamide

Chidamide is a Class I HDAC inhibitor being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effects are thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis, inhibition of epithelial to mesenchymal transition (EMT, a process that is highly relevant to tumor cell metastasis and drug resistance), induction of tumor specific antigen and antigen-specific T cell cytotoxicity, enhancement of NK cell anti-tumor activity, induction of differentiation, and resensitization of tumor cells that have become resistant to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors.

About Chipscreen

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages. The company was established as Sino-foreign joint venture in 2001.

For Chipscreen Biosciences

Rebecca Hai , (86)-755-26957317
Investor Relations
rebeccai_hai@chipscreen.com


'/>"/>
SOURCE Shenzhen Chipscreen Biosciences, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
2. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
3. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
4. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
5. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
11. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):